24 results on '"Claus, Elizabeth B"'
Search Results
2. Exogenous hormone use and meningioma risk: what do we tell our patients?
- Author
-
Claus, Elizabeth B., Black, Peter M., Bondy, Melissa L., Calvocoressi, Lisa, Schildkraut, Joellen M., Wiemels, Joseph L., and Wrensch, Margaret
- Subjects
Meningioma -- Diagnosis ,Meningioma -- Risk factors ,Meningioma -- Research ,Hormone therapy -- Research ,Hormone therapy -- Usage ,Hormone therapy -- Patient outcomes ,Oral contraceptives -- Research ,Oral contraceptives -- Usage ,Oral contraceptives -- Patient outcomes ,Tumor antigens -- Analysis ,Epidemiology -- Research ,Health - Published
- 2007
3. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER Program, 1973-2001
- Author
-
Claus, Elizabeth B. and Black, Peter M.
- Subjects
Gliomas -- Demographic aspects ,Gliomas -- Patient outcomes ,Brain tumors -- Demographic aspects ,Brain tumors -- Patient outcomes ,Epidemiology -- Research ,Cancer -- Diagnosis ,Cancer -- Demographic aspects ,Health - Published
- 2006
4. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance
- Author
-
Claus, Elizabeth B., Horlacher, Andres, Hsu, Liangge, Schwartz, Richard B., Dello-Iacono, Donna, Talos, Florian, Jolesz, Ferenc A., and Black, Peter M.
- Subjects
Excision (Surgery) -- Methods ,Excision (Surgery) -- Patient outcomes ,Magnetic resonance imaging -- Usage ,Gliomas -- Care and treatment ,Health - Published
- 2005
5. Breast carcinoma in situ: risk factors and screening patterns. (Reports)
- Author
-
Claus, Elizabeth B., Stowe, Meredith, and Carter, Darryl
- Subjects
Breast cancer -- Varieties ,Health - Abstract
Background: Risk factors associated with invasive breast cancer are well documented, but those associated with breast carcinoma in situ are not well defined. Methods: We conducted a population-based, case-control study among female residents of Connecticut to identify risk factors for breast carcinoma in situ. Case patients, diagnosed with ductal carcinoma in situ (DCIS) (n = 875) or lobular carcinoma in situ (LCIS) (n = 123), were matched by 5-year age groups with control subjects (n = 999). Case patients were diagnosed between September 15, 1994, through March 14, 1998, and all subjects were between the ages of 20 and 79 years. Information on risk factors and cancer-screening history was collected by telephone interviews. Conditional logistic regression was used to determine odds ratios (ORs) for the association of these factors with the risk of DCIS and LCIS. Results: Case patients with DCIS were more likely than control subjects to report a family history of breast cancer (OR = 1.48; 95% confidence interval [CI] = 1.19 to 1.85) or previous breast biopsy (OR = 3.56; 95% CI = 2.86 to 4.43). They also had fewer full-term pregnancies (OR = 0.86; 95% CI = 0.80 to 0.93) and were older at first full-term pregnancy (OR for being 20-29 years old relative to being < 20 years old = 1.68; 95% CI = 1.17 to 2.43) and at menopause (OR for being [greater than or equal to] 55 years old relative to being < 45 years old = 1.71; 95% CI = 1.05 to 2.77). DCIS case patients were more likely than control subjects to have had a mammographic examination (OR = 2.46; 95 % CI = 1.78 to 3.40) or an annual clinical breast examination (OR = 1.83; 95% CI = 1.48 to 2.26). DCIS patients and control subjects did not differ with respect to oral contraceptive use, hormone replacement therapy, alcohol consumption or smoking history, or breast self-examination. Associations for LCIS were similar. Conclusions: The risk factors associated with DCIS and LCIS are similar to those associated with invasive breast cancer. Diagnosis of DCIS is associated with increased mammography screening. [J Natl Cancer Inst 2001;93:1811-7]
- Published
- 2001
6. The genetic attributable risk of breast and ovarian cancer
- Author
-
Claus, Elizabeth B., Schildkraut, Joellen M., Thompson, W. Douglas, and Risch, Neil J.
- Subjects
Breast cancer -- Genetic aspects ,Ovarian cancer -- Genetic aspects ,Disease susceptibility -- Genetic aspects ,Health - Published
- 1996
7. Familial ovarian cancer: update and clinical applications
- Author
-
Claus, Elizabeth B. and Schwartz, Peter E.
- Subjects
Ovarian cancer -- Genetic aspects ,Familial diseases -- Risk factors ,Health - Published
- 1995
8. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction
- Author
-
Claus, Elizabeth B., Risch, Neil, and Thompson, W. Douglas
- Subjects
Breast cancer -- Genetic aspects ,Familial diseases -- Risk factors ,Disease susceptibility -- Genetic aspects ,Health - Abstract
Background. Improvements in screening techniques have made significant contributions to the early detection of breast cancer. Physicians thus face the task of providing appropriate screening schedules for their patients. One group for whom this is particularly important are those women with a family history of breast cancer. Methods. In this report, data from the Cancer and Steroid Hormone Study, a population-based, case-control study conducted by the Centers for Disease Control, are used to provide age-specific risk estimates of breast cancer for women with a family history of breast cancer. The data set includes 4730 patients with histologically confirmed breast cancer age 20-54 years and 4688 control subjects who were frequency matched to patients by geographic region and 5-year age intervals. The data set also includes family histories of breast cancer in mothers and sisters of both patients and control subjects. Results. Genetic models fit previously to these data by the authors have provided evidence for a rare autosomal dominant allele that results in increased susceptibility to breast cancer. In addition, these models predict that women who carry the allele are at greater risk of developing breast cancer at any age than are women who do not carry the allele. The increase in risk in carriers versus noncarriers does, however, decrease with increasing age. Based on the parameters of this model, age-specific risks for a woman with one or more relatives affected with breast cancer at various ages at onset are given. Conclusions. These tables can be used for the purpose of counseling women at high risk of breast cancer development, that is, women with a family history of breast cancer. Cancer 1994; 73:643-51.
- Published
- 1994
9. Relationship between breast histopathology and family history of breast cancer
- Author
-
Claus, Elizabeth B., Risch, Neil, Thompson, W. Douglas, and Carter, Darryl
- Subjects
Breast tumors -- Genetic aspects ,Breast cancer -- Risk factors ,Familial diseases -- Risk factors ,Mothers and daughters -- Health aspects ,Sisters -- Health aspects ,Health - Abstract
Background. The relationship between breast cancer histology and a number of epidemiologic risk factors associated with breast cancer was examined in 4071 histologically confirmed breast cancer cases aged 20 to 54 years from the Cancer and Steroid Hormone Study. Methods. The distribution of risk factors, which included a family history of breast cancer, age at onset of breast cancer, laterality, race, age at menarche, age at menopause, history of benign breast disease, parity, number of livebirths and number of stillbirths, and age at first childbirth, were examined by histologic subgroup. To determine whether histology is associated with familial risk of breast cancer, a Cox proportional hazards model was used, modeling time to onset of breast cancer among mothers and sisters. Results. Cases with medullary carcinoma were found to be significantly younger than cases with other tumor types in these data. In addition, medullary carcinoma was reported more frequently among black cases than among white cases. Cases with lobular carcinoma in situ were significantly more likely to have a mother and/or sister affected with breast cancer than cases with other tumor types and were also more likely to be bilateral, although few of these cases were both bilateral and reported a family history of breast cancer. The highest reported rates of benign breast disease occurred in cases with carcinoma in situ (both ductal and lobular) and tubular carcinoma. The remaining risk factors showed no association with histology. Conclusions. The current study clarifies the extent and nature of the relationship between breast cancer histology and epidemiologic risk factors including a family history of breast cancer. Cancer 1993; 71:147-53.
- Published
- 1993
10. Social media partnerships with patient organizations for neuro-oncology patient recruitment
- Author
-
Claus, Elizabeth B, Feliciano, Josemari, Benz, Luke S, and Calvocoressi, Lisa
- Published
- 2020
- Full Text
- View/download PDF
11. Longitudinal molecular trajectories of diffuse glioma in adults
- Author
-
Barthel, Floris P., Johnson, Kevin C., Varn, Frederick S., Moskalik, Anzhela D., Tanner, Georgette, Kocakavuk, Emre, Anderson, Kevin J., Abiola, Olajide, Aldape, Kenneth, Alfaro, Kristin D., Alpar, Donat, Amin, Samirkumar B., Ashley, David M., Bandopadhayay, Pratiti, Barnholtz-Sloan, Jill S., Beroukhim, Rameen, Bock, Christoph, Brastianos, Priscilla K., Brat, Daniel J., Brodbelt, Andrew R., Bruns, Alexander F., Bulsara, Ketan R., Chakrabarty, Aruna, Chakravarti, Arnab, Chuang, Jeffrey H., Claus, Elizabeth B., Cochran, Elizabeth J., Connelly, Jennifer, Costello, Joseph F., Finocchiaro, Gaetano, Fletcher, Michael N., French, Pim J., Gan, Hui K., Gilbert, Mark R., Gould, Peter V., Grimmer, Matthew R., Iavarone, Antonio, Ismail, Azzam, Jenkinson, Michael D., Khasraw, Mustafa, Kim, Hoon, Kouwenhoven, Mathilde C. M., LaViolette, Peter S., Li, Meihong, Lichter, Peter, Ligon, Keith L., Lowman, Allison K., Malta, Tathiane M., Mazor, Tali, McDonald, Kerrie L., Molinaro, Annette M., Nam, Do-Hyun, Nayyar, Naema, Ng, Ho Keung, Ngan, Chew Yee, Niclou, Simone P., Niers, Johanna M., Noushmehr, Houtan, Noorbakhsh, Javad, Ormond, D. Ryan, Park, Chul-Kee, Poisson, Laila M., Rabadan, Raul, Radlwimmer, Bernhard, Rao, Ganesh, Reifenberger, Guido, Sa, Jason K., Schuster, Michael, Shaw, Brian L., Short, Susan C., Smitt, Peter A. Sillevis, Sloan, Andrew E., Smits, Marion, Suzuki, Hiromichi, Tabatabai, Ghazaleh, Van Meir, Erwin G., Watts, Colin, Weller, Michael, Wesseling, Pieter, Westerman, Bart A., Widhalm, Georg, Woehrer, Adelheid, Yung, W. K. Alfred, Zadeh, Gelareh, Huse, Jason T., De Groot, John F., Stead, Lucy F., and Verhaak, Roel G. W.
- Abstract
The evolutionary processes that drive universal therapeutic resistance in adult patients with diffuse glioma remain unclear1,2. Here we analysed temporally separated DNA-sequencing data and matched clinical annotation from 222 adult patients with glioma. By analysing mutations and copy numbers across the three major subtypes of diffuse glioma, we found that driver genes detected at the initial stage of disease were retained at recurrence, whereas there was little evidence of recurrence-specific gene alterations. Treatment with alkylating agents resulted in a hypermutator phenotype at different rates across the glioma subtypes, and hypermutation was not associated with differences in overall survival. Acquired aneuploidy was frequently detected in recurrent gliomas and was characterized by IDH mutation but without co-deletion of chromosome arms 1p/19q, and further converged with acquired alterations in the cell cycle and poor outcomes. The clonal architecture of each tumour remained similar over time, but the presence of subclonal selection was associated with decreased survival. Finally, there were no differences in the levels of immunoediting between initial and recurrent gliomas. Collectively, our results suggest that the strongest selective pressures occur during early glioma development and that current therapies shape this evolution in a largely stochastic manner.
- Published
- 2019
- Full Text
- View/download PDF
12. Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial
- Author
-
Churilla, Thomas M., Chowdhury, Imran H., Handorf, Elizabeth, Collette, Laurence, Collette, Sandra, Dong, Yanqun, Alexander, Brian M., Kocher, Martin, Soffietti, Riccardo, Claus, Elizabeth B., and Weiss, Stephanie E.
- Abstract
IMPORTANCE: Brain metastases are a common source of morbidity for patients with cancer, and limited data exist to support the local therapeutic choice between surgical resection and stereotactic radiosurgery (SRS). OBJECTIVE: To evaluate local control of brain metastases among patients treated with SRS vs surgical resection within the European Organization for the Research and Treatment of Cancer (EORTC) 22952-26001 phase 3 trial. DESIGN, SETTING, AND PARTICIPANTS: This unplanned, exploratory analysis of the international, multi-institutional randomized clinical trial EORTC 22952-26001 (conducted from 1996-2007) was performed from February 9, 2017, through July 25, 2018. The EORTC 22952-26001 trial randomized patients with 1 to 3 brain metastases to whole-brain radiotherapy vs observation after complete surgical resection or before SRS. Patients in the present analysis were stratified but not randomized according to local modality (SRS or surgical resection) and treated per protocol with 1 to 2 brain metastases and tumors with a diameter of no greater than 4 cm. INTERVENTIONS: Surgical resection or SRS. MAIN OUTCOMES AND MEASURES: The primary end point was local recurrence of treated lesions. Cumulative incidence of local recurrence was calculated according to modality (surgical resection vs SRS) with competing risk regression to adjust for prognostic factors and competing risk of death. RESULTS: A total of 268 patients were included in the analysis (66.4% men; median age, 60.7 years [range, 26.9-81.1 years]); 154 (57.5%) underwent SRS and 114 (42.5%) underwent surgical resection. Median follow-up time was 39.9 months (range, 26.0-1982.0 months). Compared with the SRS group, patients undergoing surgical resection had larger metastases (median 28 mm [range, 10-40 mm] vs 20 mm [range, 4-40 mm]; P < .001), more frequently had 1 brain metastasis (112 [98.2%] vs 114 [74.0%]; P < .001), and differed in location (parietal, 21 [18.4%] vs 61 [39.6%]; posterior fossa, 30 [26.3%] vs 12 [7.8%]; P < .001). In adjusted models, local recurrence was similar between the SRS and surgical resection groups (hazard ratio [HR], 1.15; 95% CI, 0.72-1.83). However, when stratified by interval, patients with surgical resection had a much higher risk of early (0-3 months) local recurrence compared with those undergoing SRS (HR, 5.94; 95% CI, 1.72-20.45), but their risk decreased with time (HR for 3-6 months, 1.37 [95% CI, 0.64-2.90]; HR for 6-9 months, 0.75 [95% CI, 0.28-2.00]). At 9 months or longer, the surgical resection group had a lower risk of local recurrence (HR, 0.36; 95% CI, 0.14-0.93). CONCLUSIONS AND RELEVANCE: In this exploratory analysis, local control of brain metastases was similar between SRS and surgical resection groups. Stereotactic radiosurgery was associated with improved early local control of treated lesions compared with surgical resection, although the relative benefit decreased with time. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00002899
- Published
- 2019
- Full Text
- View/download PDF
13. Treatment of ruptured and unruptured cerebral aneurysms in the USA: a paradigm shift
- Author
-
Lin, Ning, Cahill, Kevin S, Frerichs, Kai U, Friedlander, Robert M, and Claus, Elizabeth B
- Abstract
BackgroundIntegration of data from clinical trials and advancements in technology predict a change in selection for treatment of patients with cerebral aneurysm.ObjectiveTo describe patterns of use and in-hospital mortality associated with surgical and endovascular treatments of cerebral aneurysms over the past decade.Materials and methodsThe data are 34 899 hospital discharges with a diagnosis of ruptured or unruptured cerebral aneurysm from 1998 to 2007 identified from the Nationwide Inpatient Sample (NIS). The rates of endovascular coiling and surgical clipping and in-hospital mortality among patients with an aneurysm are examined over a decade by hospital and patient demographic characteristics.ResultsFrom 1998 to 2007, 20 134 discharges with a ruptured aneurysm and 14 765 discharges with an unruptured aneurysm were identified. Over this decade, the number of patients discharged with a ruptured aneurysm was stable while the number discharged with an unruptured aneurysm increased significantly. The use of endovascular coiling increased at least twofold for both groups of patient (p<0.001) with the majority of unruptured aneurysms treated with coiling by 2007. Although whites were more likely than non-whites to undergo coiling versus clipping for a ruptured aneurysm (OR=1.30; 95% CI 1.13 to 1.48) and men with unruptured aneurysms were more likely than women to undergo coiling (OR=1.26; 95% CI 1.13 to 1.40), by 2007 differences in treatment selection by gender and racial subgroups were decreased or statistically non-significant. Over time the use of coiling spread from primarily large, teaching hospitals to smaller, non-teaching hospitals.ConclusionsThe majority of unruptured aneurysms in the USA are now treated with endovascular coiling. Although surgical clipping is used for treatment of most ruptured aneurysms, its use is decreasing over time. Dissemination of endovascular procedures appears widespread across patient and hospital subgroups.
- Published
- 2018
- Full Text
- View/download PDF
14. Unplanned Reoperation After Craniotomy for Tumor: A National Surgical Quality Improvement Program Analysis
- Author
-
Dasenbrock, Hormuzdiyar H, Yan, Sandra C, Chavakula, Vamsi, Gormley, William B, Smith, Timothy R, Claus, Elizabeth B, and Dunn, Ian F
- Published
- 2017
- Full Text
- View/download PDF
15. Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study
- Author
-
Martin, Allison M., Cagney, Daniel N., Catalano, Paul J., Warren, Laura E., Bellon, Jennifer R., Punglia, Rinaa S., Claus, Elizabeth B., Lee, Eudocia Q., Wen, Patrick Y., Haas-Kogan, Daphne A., Alexander, Brian M., Lin, Nancy U., and Aizer, Ayal A.
- Abstract
IMPORTANCE: Population-based estimates of the incidence and prognosis of brain metastases at diagnosis of breast cancer are lacking. OBJECTIVE: To characterize the incidence proportions and median survivals of patients with breast cancer and brain metastases at the time of cancer diagnosis. DESIGN, SETTING, AND PARTICIPANTS: Patients with breast cancer and brain metastases at the time of diagnosis were identified using the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute. Data were stratified by subtype, age, sex, and race. Multivariable logistic and Cox regression were performed to identify predictors of the presence of brain metastases at diagnosis and factors associated with all-cause mortality, respectively. For incidence, we identified a population-based sample of 238 726 adult patients diagnosed as having invasive breast cancer between 2010 and 2013 for whom the presence or absence of brain metastases at diagnosis was known. Patients diagnosed at autopsy or with an unknown follow-up were excluded from the survival analysis, leaving 231 684 patients in this cohort. MAIN OUTCOMES AND MEASURES: Incidence proportion and median survival of patients with brain metastases and newly diagnosed breast cancer. RESULTS: We identified 968 patients with brain metastases at the time of diagnosis of breast cancer, representing 0.41% of the entire cohort and 7.56% of the subset with metastatic disease to any site. A total of 57 were 18 to 40 years old, 423 were 41 to 60 years old, 425 were 61-80 years old, and 63 were older than 80 years. Ten were male and 958 were female. Incidence proportions were highest among patients with hormone receptor (HR)-negative human epidermal growth factor receptor 2 (HER2)-positive (1.1% among entire cohort, 11.5% among patients with metastatic disease to any distant site) and triple-negative (0.7% among entire cohort, 11.4% among patients with metastatic disease to any distant site) subtypes. Median survival among the entire cohort with brain metastases was 10.0 months. Patients with HR-positive HER2-positive subtype displayed the longest median survival (21.0 months); patients with triple-negative subtype had the shortest median survival (6.0 months). CONCLUSIONS AND RELEVANCE: The findings of this study provides population-based estimates of the incidence and prognosis for patients with brain metastases at time of diagnosis of breast cancer. The findings lend support to consideration of screening imaging of the brain for patients with HER2-positive or triple-negative subtypes and extracranial metastases.
- Published
- 2017
- Full Text
- View/download PDF
16. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors
- Author
-
Melin, Beatrice S, Barnholtz-Sloan, Jill S, Wrensch, Margaret R, Johansen, Christoffer, Il'yasova, Dora, Kinnersley, Ben, Ostrom, Quinn T, Labreche, Karim, Chen, Yanwen, Armstrong, Georgina, Liu, Yanhong, Eckel-Passow, Jeanette E, Decker, Paul A, Labussière, Marianne, Idbaih, Ahmed, Hoang-Xuan, Khe, Di Stefano, Anna-Luisa, Mokhtari, Karima, Delattre, Jean-Yves, Broderick, Peter, Galan, Pilar, Gousias, Konstantinos, Schramm, Johannes, Schoemaker, Minouk J, Fleming, Sarah J, Herms, Stefan, Heilmann, Stefanie, Nöthen, Markus M, Wichmann, Heinz-Erich, Schreiber, Stefan, Swerdlow, Anthony, Lathrop, Mark, Simon, Matthias, Sanson, Marc, Andersson, Ulrika, Rajaraman, Preetha, Chanock, Stephen, Linet, Martha, Wang, Zhaoming, Yeager, Meredith, Wiencke, John K, Hansen, Helen, McCoy, Lucie, Rice, Terri, Kosel, Matthew L, Sicotte, Hugues, Amos, Christopher I, Bernstein, Jonine L, Davis, Faith, Lachance, Dan, Lau, Ching, Merrell, Ryan T, Shildkraut, Joellen, Ali-Osman, Francis, Sadetzki, Siegal, Scheurer, Michael, Shete, Sanjay, Lai, Rose K, Claus, Elizabeth B, Olson, Sara H, Jenkins, Robert B, Houlston, Richard S, and Bondy, Melissa L
- Abstract
Genome-wide association studies (GWAS) have transformed our understanding of glioma susceptibility, but individual studies have had limited power to identify risk loci. We performed a meta-analysis of existing GWAS and two new GWAS, which totaled 12,496 cases and 18,190 controls. We identified five new loci for glioblastoma (GBM) at 1p31.3 (rs12752552; P = 2.04 × 10−9, odds ratio (OR) = 1.22), 11q14.1 (rs11233250; P = 9.95 × 10−10, OR = 1.24), 16p13.3 (rs2562152; P = 1.93 × 10−8, OR = 1.21), 16q12.1 (rs10852606; P = 1.29 × 10−11, OR = 1.18) and 22q13.1 (rs2235573; P = 1.76 × 10−10, OR = 1.15), as well as eight loci for non-GBM tumors at 1q32.1 (rs4252707; P = 3.34 × 10−9, OR = 1.19), 1q44 (rs12076373; P = 2.63 × 10−10, OR = 1.23), 2q33.3 (rs7572263; P = 2.18 × 10−10, OR = 1.20), 3p14.1 (rs11706832; P = 7.66 × 10−9, OR = 1.15), 10q24.33 (rs11598018; P = 3.39 × 10−8, OR = 1.14), 11q21 (rs7107785; P = 3.87 × 10−10, OR = 1.16), 14q12 (rs10131032; P = 5.07 × 10−11, OR = 1.33) and 16p13.3 (rs3751667; P = 2.61 × 10−9, OR = 1.18). These data substantiate that genetic susceptibility to GBM and non-GBM tumors are highly distinct, which likely reflects different etiology.
- Published
- 2017
- Full Text
- View/download PDF
17. Readmission After Craniotomy for Tumor: A National Surgical Quality Improvement Program Analysis
- Author
-
Dasenbrock, Hormuzdiyar H., Yan, Sandra C., Smith, Timothy R., Valdes, Pablo A., Gormley, William B., Claus, Elizabeth B., and Dunn, Ian F.
- Abstract
BACKGROUND:Although readmission has become a common quality indicator, few national studies have examined this metric in patients undergoing cranial surgery.OBJECTIVE:To utilize the prospective National Surgical Quality Improvement Program 2011-2013 registry to evaluate the predictors of unplanned 30-d readmission and postdischarge mortality after cranial tumor resection.METHODS:Multivariable logistic regression was applied to screen predictors, which included patient age, sex, tumor location and histology, American Society of Anesthesiologists class, functional status, comorbidities, and complications from the index hospitalization.RESULTS:Of the 9565 patients included, 10.7% (n = 1026) had an unplanned readmission. Independent predictors of unplanned readmission were male sex, infratentorial location, American Society of Anesthesiologists class 3 designation, dependent functional status, a bleeding disorder, and morbid obesity (all P≤ .03). Readmission was not associated with operative time, length of hospitalization, discharge disposition, or complications from the index admission. The most common reasons for readmission were surgical site infections (17.0%), infectious complications (11.0%), venous thromboembolism (10.0%), and seizures (9.4%). The 30-d mortality rate was 3.2% (n = 367), of which the majority (69.7%, n = 223) occurred postdischarge. Independent predictors of postdischarge mortality were greater age, metastatic histology, dependent functional status, hypertension, discharge to institutional care, and postdischarge neurological or cardiopulmonary complications (all P< .05).CONCLUSION:Readmissions were common after cranial tumor resection and often attributable to new postdischarge complications rather than exacerbations of complications from the initial hospitalization. Moreover, the majority of 30-d deaths occurred after discharge from the index hospitalization. The preponderance of postdischarge mortality and complications requiring readmission highlights the importance of posthospitalization management.
- Published
- 2017
- Full Text
- View/download PDF
18. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases
- Author
-
Ni, Jing, Ramkissoon, Shakti H, Xie, Shaozhen, Goel, Shom, Stover, Daniel G, Guo, Hanbing, Luu, Victor, Marco, Eugenio, Ramkissoon, Lori A, Kang, Yun Jee, Hayashi, Marika, Nguyen, Quang-De, Ligon, Azra H, Du, Rose, Claus, Elizabeth B, Alexander, Brian M, Yuan, Guo-Cheng, Wang, Zhigang C, Iglehart, J Dirk, Krop, Ian E, Roberts, Thomas M, Winer, Eric P, Lin, Nancy U, Ligon, Keith L, and Zhao, Jean J
- Abstract
Brain metastases represent the greatest clinical challenge in treating HER2-positive breast cancer. We report the development of orthotopic patient-derived xenografts (PDXs) of HER2-expressing breast cancer brain metastases (BCBM), and their use for the identification of targeted combination therapies. Combined inhibition of PI3K and mTOR resulted in durable tumor regressions in three of five PDXs, and therapeutic response was correlated with a reduction in the phosphorylation of 4EBP1, an mTORC1 effector. The two nonresponding PDXs showed hypermutated genomes with enrichment of mutations in DNA-repair genes, which suggests an association of genomic instability with therapeutic resistance. These findings suggest that a biomarker-driven clinical trial of PI3K inhibitor in combination with an mTOR inhibitor should be conducted for patients with HER2-positive BCBM.
- Published
- 2016
- Full Text
- View/download PDF
19. Neurosurgical management of metastases in the central nervous system
- Author
-
Claus, Elizabeth B.
- Abstract
Rates of central nervous system (CNS) involvement in metastatic cancer are believed to be increasing. The neurosurgical treatment of patients with metastatic cancer is an integral component of multimodality therapy for brain and spinal metastases. This Review discusses data from current randomized clinical trials that examine the role of neurosurgical intervention in the treatment of patients with CNS metastases.
- Published
- 2012
- Full Text
- View/download PDF
20. Pathobiologic Findings in DCIS of the Breast: Morphologic Features, Angiogenesis, HER-2/neuand Hormone Receptors
- Author
-
Claus, Elizabeth B., Chu, Peiguo, Howe, Christine L., Davison, Tracey L., Stern, David F., Carter, Darryl, and DiGiovanna, Michael P.
- Abstract
With the increasing incidence of ductal carcinoma in situ(DCIS) of the breast and its relationship to invasive breast carcinoma, it is important to understand the biology of this entity. We report on a hospital-based survey of 219 case subjects with DCIS of the breast without associated invasive carcinoma diagnosed between 1982 and 1994. The cases of DCIS were analyzed for architectural type, size, nuclear grade, necrosis, calcification, periductal fibrosis, neovascularization, estrogen receptor (ER), progesterone receptor (PR), and HER-2/neuexpression. Periductal neovascularization was associated with tumor size, microcalcifications, periductal fibrosis, and HER-2/neuoverexpression. Expression of ER and PR was observed in 60 and 62% of the cases, respectively, and HER-2/neuoverexpression in 28% of the cases. ER and PR expression were both inversely associated with comedo histology and nuclear grade. HER-2/neuoverexpression was positively associated with comedo histology, high nuclear grade, and periductal neovascularization and was inversely correlated with both ER and PR expression. High nuclear grade was positively associated with comedocarcinoma, necrosis, microcalcification, and periductal fibrosis. The role of these molecular/pathologic markers in the biology of DCIS and their potential clinical implications are discussed.
- Published
- 2001
- Full Text
- View/download PDF
21. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer
- Author
-
Claus, Elizabeth B., Risch, Neil, and Thompson, W. Douglas
- Abstract
Recent linkage analyses demonstrate the strength of the genetic association between breast and ovarian cancer in some families. These findings highlight the importance of considering a woman's family history of ovarian cancer in the calculation of her risk of breast cancer. In this study, data on breast and ovarian cancer from the Cancer and Steroid Hormone Study, a large, population-based, case-control study conducted by the Centers for Disease Control, are used to calculate age-specific and cumulative risks of developing breast cancer for a woman with a first degree family history of ovarian cancer. These risks are calculated using maximum likelihood estimates from an autosomal dominant genetic model fit previously to the observed age-specific recurrence data of breast cancer among first degree relatives of the breast cancer cases and controls in these data as well as from genotype-specific estimates of lifetime ovarian cancer risk derived from this model. Under this model, the lifetime risk of developing breast cancer for a woman with one or two first degree relatives affected with ovarian cancer is estimated to be approximately 13% and 31%, respectively. A woman with one first degree relative affected with ovarian cancer and one first degree relative affected with breast cancer has an estimated risk of 40 percent of developing breast cancer by age 79 years if the relative with breast cancer was diagnosed in her thirties. This risk decreases with increasing age of onset of the relative affected with breast cancer.
- Published
- 1993
- Full Text
- View/download PDF
22. The Contribution of Predisposing and Situational Risk Factors to Serious Fall Injuries
- Author
-
Tinetti, Mary E., Doucette, John T., and Claus, Elizabeth B.
- Abstract
OBJECTIVES:The objectives were to identify situational risk factors associated with suffering a serious fall injury and to determine whether, and to what extent, predisposing and situational risk factors contributed independently to risk of suffering a serious fall injury.
- Published
- 1995
- Full Text
- View/download PDF
23. Autosomal Dominant Inheritance of EarlyOnset Breast Cancer
- Author
-
Claus, Elizabeth B., Risch, Neil, and Thompson, W. Douglas
- Published
- 1994
24. THE AUTHORS REPLY
- Author
-
Claus, Elizabeth B., Risch, Neil J., and Thompson, W. Douglas
- Published
- 1992
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.